Lacrimal Gland DLBCL: Diagnostic Work-up and First-Line Treatment
For lacrimal gland DLBCL, obtain a surgical biopsy for diagnosis, stage with FDG-PET/CT, calculate IPI score, and treat with R-CHOP × 6 cycles (or Pola-R-CHP for IPI ≥2) followed by consideration of radiotherapy to the lacrimal site.
Diagnostic Work-up
Tissue Diagnosis
- Surgical excisional biopsy is mandatory for lacrimal gland masses suspicious for lymphoma 1. The lacrimal sac location can mimic chronic dacryocystitis, leading to diagnostic delays 2, so maintain high clinical suspicion for any growing mass in this region.
- Fine-needle aspiration is inadequate and should not be used 1
- Confirm B-cell lineage with immunophenotypic studies 1
- Assess MYC and BCL2 rearrangements by FISH in all newly diagnosed patients treated with curative intent 1—this identifies high-risk "double-hit" lymphomas requiring potentially different management
Staging Evaluation
The following are required 1:
- FDG-PET/CT scan (gold standard for staging)
- Physical examination with performance status and B symptoms assessment
- Complete blood count, LDH, uric acid, liver/kidney function
- HIV, HBV, and HCV screening (mandatory)
- Protein electrophoresis
- Cardiac function assessment (LVEF) before anthracycline-based therapy
- Calculate IPI score (age, stage, LDH, performance status, extranodal sites)
CNS Risk Assessment
For lacrimal gland DLBCL specifically:
- MRI of orbits and brain to assess local extension 1
- Consider diagnostic lumbar puncture in high-risk patients 1
- The lacrimal gland represents an extranodal site, which contributes to IPI scoring and may warrant CNS prophylaxis consideration, though evidence for routine prophylaxis remains uncertain 3
First-Line Treatment
Treatment Selection Based on Risk Stratification
For IPI 0-1 (Low Risk):
- R-CHOP × 6 cycles every 21 days remains standard 1
- Recent data support abbreviated therapy (4 cycles) for young, low-risk patients with negative interim PET, though this applies primarily to nodal disease 4
For IPI ≥2 (Higher Risk):
- Polatuzumab vedotin-R-CHP (Pola-R-CHP) is now preferred over standard R-CHOP based on the POLARIX trial showing superior progression-free survival 3, 4
- This represents the most significant advance in first-line DLBCL treatment in two decades
Radiotherapy Considerations
- For localized lacrimal gland involvement, consolidation radiotherapy to the involved site should be considered after chemotherapy 5
- While consolidation radiotherapy to non-bulky sites has no proven benefit in rituximab-treated patients with nodal disease 1, extranodal sites like the lacrimal gland may benefit from local control, particularly given the functional importance of preserving vision
- Case reports demonstrate successful outcomes combining chemotherapy with radiotherapy for lacrimal sac DLBCL 5
Supportive Care
- G-CSF prophylaxis for patients >60 years or those at high risk for febrile neutropenia 1
- Tumor lysis syndrome prophylaxis if high tumor burden 1
- Avoid dose reductions for hematologic toxicity whenever possible 1
Common Pitfalls
Misdiagnosis as dacryocystitis: Lacrimal sac DLBCL commonly presents with epiphora and swelling mimicking chronic dacryocystitis 2. Any growing mass or atypical features warrant immediate biopsy before proceeding with dacryocystorhinostomy.
Inadequate tissue sampling: Core needle biopsies may be insufficient for complete molecular characterization. Surgical excision provides optimal tissue for MYC/BCL2 assessment 1.
Delayed CNS evaluation: Given the extranodal location near the CNS, ensure brain MRI and consider CSF analysis in high-risk patients 3.
Undertreatment in elderly patients: While dose-reduced R-miniCHOP may be appropriate for frail patients ≥80 years 3, fit elderly patients should receive full-dose therapy with appropriate supportive care 1.